Inhibition of angiogenesis by recombinant VEGF receptor fragments

Laboratory Medicine

Volumn 41, Issue 7, 2010, Pages 417-422

  Ahmadvand, Davoud ^a   Rahbarizadeh, Fatemeh ^b   Iri Sofla, Farnoush Jafari ^b   Namazi, Gholamreza ^c   Khaleghi, Sepideh ^b   Geramizadeh, Bita ^d   Pasalar, Parvin ^c   Karimi, Hosein ^d   Bakhtiari, Seyed Hamid Aghaee ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Angiogenesis; Expression; VEGFR fragments

Indexed keywords

VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; ARTICLE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY; IMMUNOBLOTTING; POLYACRYLAMIDE GEL ELECTROPHORESIS; UMBILICAL VEIN;

ESCHERICHIA COLI;

EID: 77954753854     PISSN: 00075027     EISSN: 19437730     Source Type: Journal    
DOI: 10.1309/LMMH2WYRLP7B3HJN     Document Type: Article

References (33)

1. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671-674.
2. Qiu Y, Hoareau-Aveilla C, Oltean S, et al. The anti-angiogenic isoforms of VEGF in health and disease. Biochem Soc Trans. 2009;37:1207-1213.
3. Schipani E, Maes C, Carmeliet G, et al. Regulation of osteogenesis-angiogenesis coupling by HIFs and VEGF. J Bone Miner Res. 2009;24:1347-1353.
4. Shibuya M. Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv Cancer Res. 1995;67:281-316.
5. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2:795-803. (Pubitemid 37328914)
6. de Vries C, Escobedo JA, Ueno H, et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 1992;255:989-991.
7. Ellis LM, Hicklin DJ. VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8:579-591.
8. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676.
9. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol. 2006;39:469-478.
10. Holmes K, Roberts OL, Thomas AM, et al. Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition. Cell Signal. 2007;19:2003-2012. (Pubitemid 47354167)
11. Tanaka K, Yamaguchi S, Sawano A, et al. Characterization of the extracellular domain in vascular endothelial growth factor receptor-1 (Flt-1 tyrosine kinase). Jpn J Cancer Res. 1997;88:867-876. (Pubitemid 27475089)
12. Matsumoto T, Claesson-Welsh L. VEGF receptor signal transduction. Sci STKE. 2001;2001:re21.
13. Otrock ZK, Makarem JA, Shamseddine AI. Vascular endothelial growth factor family of ligands and receptors: Review. Blood Cells Mol Dis. 2007;38:258-268. (Pubitemid 46518176)
14. Kou B, Li Y, Zhang L, et al. In vivo inhibition of tumor angiogenesis by a soluble VEGFR-2 fragment. Exp Mol Pathol. 2004;76:129-137. (Pubitemid 38316928)
15. Izuta H, Shimazawa M, Tsuruma K, et al. Bee products prevent VEGF-induced angiogenesis in human umbilical vein endothelial cells. BMC Complement Altern Med. 2009;9:45.
16. Vitaliti A, Wittmer M, Steiner R, et al. Inhibition of tumor angiogenesis by a single-chain antibody directed against vascular endothelial growth factor. Cancer Res. 2000;60:4311-4314. (Pubitemid 32103600)
17. Popkov M, Jendreyko N, Gonzalez-Sapienza G, et al. Human/mouse cross-reactive anti-VEGF receptor 2 recombinant antibodies selected from an immune b9 allotype rabbit antibody library. J Immunol Methods. 2004;288:149-164. (Pubitemid 38739260)
18. Sambrook J, Russell DW. Molecular Cloning: A Laboratory Manual. 3rd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2001.
19. Rahbarizadeh F, Rasaee MJ, Forouzandeh-Moghadam M, et al. High expression and purification of the recombinant camelid anti-MUC1 single domain antibodies in Escherichia coli. Protein Expr Purif. 2005;44:32-38.
20. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
21. Ausubel FM, Brent R, Kingston RE, et al. Short Protocols in Molecular Biology. 4th ed. New York, NY: Wiley; 1999.
22. Ahmadvand D, Rasaee MJ, Rahbarizadeh F, et al. Cell selection and characterization of a novel human endothelial cell specific nanobody. Mol Immunol. 2009;46:1814-1823.
23. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
24. She X, Matsuno F, Harada N, et al. Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells. Int J Cancer. 2004;108:251-257.
25. Brekken RA, Overholser JP, Stastny VA, et al. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res. 2000;60:5117-5124.
26. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science. 2005;307:58-62.
27. Halin C, Zardi L, Neri D. Antibody-based targeting of angiogenesis. News Physiol Sci. 2001;16:191-194.
28. Lu D, Jimenez X, Zhang H, et al. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor. Cancer Res. 2001;61:7002-7008.
29. Scott A, Mellor H. VEGF receptor trafficking in angiogenesis. Biochem Soc Trans. 2009;37:1184-1188.
30. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. 2001;61:6624-6628.
31. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med. 1971;285:1182-1186.
32. Zhu Z, Witte L. Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest New Drugs. 1999;17:195-212.
33. Mǎrgǎritescu C, Pirici D, Simionescu C, et al. VEGF and VEGFRs expression in oral squamous cell carcinoma. Rom J Morphol Embryol. 2009;50:527-548.